Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125649462 | 12564946 | 2 | F | 2014 | 20160714 | 20160718 | 20160725 | EXP | DE-MLMSERVICE-20160630-0322609-1 | DE-ACCORD-042413 | ACCORD | GOERIG N, SEMRAU S, FREY B, KORN K, FLECKENSTEIN B, UBERLA K ET AL. CLINICALLY SIGNIFICANT CMV (RE)ACTIVATION DURING OR AFTER RADIOTHERAPY/CHEMOTHERAPY OF THE BRAIN: CORRELATION WITH NEUROLOGICAL DETERIORATION AND IMPROVEMENT UPON ANTIVIRAL TREATMENT.STRAHLENTHERAPIE UND ONKOLOGIE. 2016; 1-9 | 63.00 | YR | F | Y | 0.00000 | 20160725 | OT | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125649462 | 12564946 | 1 | PS | CISPLATIN. | CISPLATIN | 1 | KOF; 100% | 206774 | 75 | MG/M**2 | |||||||||
| 125649462 | 12564946 | 2 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | KOF: 100% | 74513 | 100 | MG/M**2 | |||||||||
| 125649462 | 12564946 | 3 | SS | LEVETIRACETAM. | LEVETIRACETAM | 1 | 90843 | ||||||||||||
| 125649462 | 12564946 | 4 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | 0 | 4 | MG | QID | |||||||||
| 125649462 | 12564946 | 5 | SS | MANNITOL. | MANNITOL | 1 | 0 | 20 | PCT | QD | |||||||||
| 125649462 | 12564946 | 6 | SS | NALOXONE | NALOXONE | 1 | 0 | ||||||||||||
| 125649462 | 12564946 | 7 | C | MORPHINE | MORPHINE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125649462 | 12564946 | 1 | Metastases to central nervous system |
| 125649462 | 12564946 | 2 | Metastases to central nervous system |
| 125649462 | 12564946 | 3 | Product used for unknown indication |
| 125649462 | 12564946 | 4 | Product used for unknown indication |
| 125649462 | 12564946 | 5 | Product used for unknown indication |
| 125649462 | 12564946 | 6 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125649462 | 12564946 | LT |
| 125649462 | 12564946 | OT |
| 125649462 | 12564946 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125649462 | 12564946 | Coma | |
| 125649462 | 12564946 | Cytomegalovirus infection | |
| 125649462 | 12564946 | Disorientation | |
| 125649462 | 12564946 | Drug ineffective | |
| 125649462 | 12564946 | Febrile neutropenia | |
| 125649462 | 12564946 | Off label use | |
| 125649462 | 12564946 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125649462 | 12564946 | 1 | 2014 | 0 | ||
| 125649462 | 12564946 | 2 | 2014 | 0 | ||
| 125649462 | 12564946 | 3 | 201410 | 0 | ||
| 125649462 | 12564946 | 4 | 201410 | 20141010 | 0 | |
| 125649462 | 12564946 | 5 | 201410 | 20141010 | 0 | |
| 125649462 | 12564946 | 6 | 201410 | 0 | ||
| 125649462 | 12564946 | 7 | 201410 | 0 |